Accelerate Your Real-World Evidence Goals Through Exclusive Insights and Expertise from Industry Leaders

RWE-Landing-Page-Header-1-2x
casestudy1@2x

What can we do for you?

Discover timely, actionable real-world evidence to improve patient experience and outcomes.

Complete this short form for a feasibility assessment, or to talk to one of our experts about your needs.

 

Make Sure Your Data is in the Right Hands

It can be a daunting task to generate meaningful insights from often disparate sources of real-world data (RWD). Your teams are moving fast to solve today’s health challenges and can’t afford to waste valuable time and resources trying to generate valuable insights form these fragmented sources of data.

Whether you’re coming to us with data sourced from the Veradigm Network or from a third-party, our team of industry veterans is well-positioned to support your real-world evidence goals.

RWE-Landing-Page-Sect9-2x

Veradigm’s Real-World Evidence team can help you leverage real-world practice data to generate insights for:

  • Epidemiology, Health Economics and Outcomes Research (HEOR), and Market Access initiatives

  • Registry and study implementation utilizing data extracted from electronic health record (EHR) systems, registries and linked administrative claims databases

  • Real world evidence communication plans through internal reports and peer-reviewed manuscripts and presentations

Actionable Real-World Evidence Starts with Veradigm

With a team of analytics experts at your fingertips, you’ll be able to:
  • Build analytics services that requires less extrapolation because they are based on real-world data
  • Tap into a range of market access, retrospective, and observational services and studies
  • Address safety surveillance, reimbursement, health economics, and brand analysis with retrospective and prospective approaches
  • Leverage the Veradigm Network’s deep relationships with clinical practices for efficient case ascertainment

Notable case studies 

RWE-Landing-Page-Case-Study1-2x

Relative Effectiveness of MF59® Adjuvanted Trivalent Influenza Vaccine Versus Non-Adjuvanted Vaccines

In this study, the Veradigm RWE team collaborated with Seqirus researchers to compare the rate of influenza-related medical encounters using a linked EHR + claims database.

The analysis controlled for differences in patient characteristics using a doubly robust approach of IPTW paired with multivariate analysis to equitably compare different influenza vaccines during the 2019-2020 influenza season.

COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort

Through a collaboration with HealthPals, Veradigm researchers leveraged a large EHR + claims linked database to evaluate the risk of venous and arterial thrombotic events following COVID-19 infection using a historical influenza cohorts. This analysis was part of a larger volunteer effort through the Reagan-Udall Evidence Accelerator.

RWE-Landing-Page-Case-Study2-2x
RWE-Landing-Page-Case-Study3-2x

A Qualitative Analysis of Provider Notes of Atopic Dermatitis-Related Visits Using Natural Language Processing Methods

Leveraging physician notes, Veradigm researchers identified atopic dermatitis events in the Practice Fusion EHR, setting the stage for deeper analysis into analyses of atopic dermatitis severity and flares. The teams later tied this clinical concepts to changes in healthcare resource utilization and costs.

Early Use of Erenumab in US Real-World Practice

Taking advantage of the short data lag associated with EHR data, Veradigm researchers characterized early users of erenumab for the treatment of migraine. Erenumab was part of a new class of medications emerging for the prevention of migraine, a condition previously managed through medications primarily indicated for other conditions but characterized by poor treatment persistence and limited efficacy.

RWE-Landing-Page-Case-Study4-2x

What can we do for you?
Contact us for a feasibility consultation.